| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012798 Physiologically active substance eem-s originating in mushroms, process for producing the same and drugs |
| 01/16/2003 | US20030012794 Kits comprising heat shock protein-antigenic molecule complexes |
| 01/16/2003 | US20030012791 Use of cytokines and mitogens to inhibit graft versus host disease |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012782 Method and composition for altering a T cell mediated pathology |
| 01/16/2003 | US20030012781 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | CA2785699A1 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452695A1 Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis |
| 01/16/2003 | CA2452628A1 Methylation of histone h4 at arginine 3 |
| 01/16/2003 | CA2452609A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | CA2452603A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | CA2452597A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | CA2452578A1 Ephrin and eph receptor mediated immune modulation |
| 01/16/2003 | CA2452501A1 Secreted proteins |
| 01/16/2003 | CA2452372A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | CA2452119A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | CA2451749A1 Novel immunomodulating compounds |
| 01/16/2003 | CA2451738A1 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine |
| 01/16/2003 | CA2451606A1 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | CA2450502A1 Epf receptor assays, compounds and therapeutic compositions |
| 01/15/2003 | EP1275720A2 Histidyl-trna synthetase of staphylococcus aureus |
| 01/15/2003 | EP1275638A1 Combination therapy for the treatment of immunological disorders |
| 01/15/2003 | EP1275392A2 Prolactin inhibiting or stimulating compounds to regulate the immune function |
| 01/15/2003 | EP1275388A1 Tnf- alpha inhibitors |
| 01/15/2003 | EP1275379A2 Basic granulate comprising (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one |
| 01/15/2003 | EP1274853A1 Materials and methods relating to immune responses to fusion proteins |
| 01/15/2003 | EP1274852A2 Targeted vaccine delivery systems |
| 01/15/2003 | EP1274851A1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274841A2 Regulation of human cyslt2-like gpcr protein |
| 01/15/2003 | EP1274840A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 01/15/2003 | EP1274833A2 A method to prevent graft rejection using tgf-beta to induce t suppressor cells |
| 01/15/2003 | EP1274733A1 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274705A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| 01/15/2003 | EP1274701A1 Chemical compounds |
| 01/15/2003 | EP1274697A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 01/15/2003 | EP1274694A1 Novel compounds |
| 01/15/2003 | EP1274692A1 Quinazoline compounds |
| 01/15/2003 | EP1274457A2 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| 01/15/2003 | EP1274455A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 01/15/2003 | EP1274454A2 Methods and compositions for eliciting an immune response |
| 01/15/2003 | EP1274453A2 Recombinant intracellular pathogen vaccines and methods for use |
| 01/15/2003 | EP1274450A2 Cytokine uses; compositions; methods |
| 01/15/2003 | EP1274446A1 Polysaccharidic esters of n-derivatives of glutamic acid |
| 01/15/2003 | EP1274428A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274415A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274413A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274407A2 Uses of ppar-gamma agonists in neutrophil-induced diseases |
| 01/15/2003 | EP1107779B1 Medicaments for manipulating t-cell immune response |
| 01/15/2003 | EP0925287B1 Heterocyclic metalloprotease inhibitors |
| 01/15/2003 | EP0713483B1 Amidine derivatives with nitric oxide synthetase activities |
| 01/15/2003 | EP0671927B1 Human neutralizing monoclonal antibodies to respiratory syncytial virus |
| 01/15/2003 | EP0649412B1 Pharmaceutical pyridine compounds |
| 01/15/2003 | EP0584347B1 Enantiomeric hydroxylated xanthine compounds |
| 01/15/2003 | CN1391609A Use of replication-deficient adenoviral vector to boost CD8+T cell immune response to antigen |
| 01/15/2003 | CN1391608A Cloning, expression and characterisation of gene expressed in tumour cells and involved in regulation of immune response |
| 01/15/2003 | CN1391580A Peptides |
| 01/15/2003 | CN1391571A Heterocyclic compounds and their use as medicines |
| 01/15/2003 | CN1391570A Phenyl-and pyridyl-tetrahydro-pyridines having TNF inhibiting activity |
| 01/15/2003 | CN1391556A IL-8 receptor antagonists |
| 01/15/2003 | CN1391483A Composition of octoxinol and polyvinyl chloride sorbitanate as accessory and uses in vaccins |
| 01/15/2003 | CN1391481A 疫苗 Vaccine |
| 01/15/2003 | CN1391480A Compositions and methods for treatment of allergic disorders |
| 01/15/2003 | CN1391479A Medicament for inducing tolerance |
| 01/15/2003 | CN1391475A Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| 01/15/2003 | CN1391474A 5-membered heterocycle derivatives, production thereof and use as medicaments |
| 01/15/2003 | CN1391473A VLA-4 inhibitor compounds |
| 01/15/2003 | CN1390832A N,N'-diacetylcystine-arginine salt and its preparing process and usage |
| 01/15/2003 | CN1390603A Applicaltion of buthotoxin Bmk AS in preparing medicines |
| 01/15/2003 | CN1390594A Mixture for improving blood circulation |
| 01/15/2003 | CN1098930C GRB3-3 gene, variants and uses thereof |
| 01/15/2003 | CN1098707C Medicinal composition containing algal protein polyose extract and extraction of algal protein polyose |
| 01/15/2003 | CN1098691C Propolis honey and its preparing process |
| 01/15/2003 | CN1098686C Use of xanthine derivatives for reducing pathological hyper-reactivity of eosinophilic granulocytes, xanthine compounds and process for producing them |
| 01/14/2003 | US6506912 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506802 Disulfide derivatives useful for treating allergic diseases |
| 01/14/2003 | US6506796 Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of |
| 01/14/2003 | US6506787 Aids therapy |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506773 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506772 Pharmaceutically active salts thereof with activity as adenosine receptor ligands are disclosed. These compounds are the adenosine receptor. |
| 01/14/2003 | US6506766 Glucocortiocoid-selective antinflammatory agents |
| 01/14/2003 | US6506756 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 01/14/2003 | US6506750 Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/14/2003 | US6506748 Aromatic heterocyclic compounds as antiinflammatory agents |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506582 Extended by aspartic acid at 5' end and shortened at 3' end by one to eight amino acids; nonimmunogenic; binds CD4 lymphocytes |
| 01/14/2003 | US6506555 Use of HIV protease inhibiting compounds |
| 01/14/2003 | US6506388 Treating pollinosis using substance obtained by dissolving cell wall of corynebacterlum glutamicum with one of glucosi-dase and endopeptidase in isotonic solution medium, separa-ting protoplasts and treating with the other enzyme |
| 01/14/2003 | US6506386 Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent |
| 01/14/2003 | US6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies |